146 related articles for article (PubMed ID: 25454599)
1. [Drug Rash with Eosinophilia and Systemic Symptoms syndrome induced by telaprevir in a patient with chronic hepatitis C virus infection].
Martín Domínguez V; Carrascosa de Lome R; Becerro González I; de Argila D; Villar K; García-Buey L
Gastroenterol Hepatol; 2015 Oct; 38(8):491-3. PubMed ID: 25454599
[No Abstract] [Full Text] [Related]
2. Telaprevir-induced DRESS.
Kesar V; Kesar V; Khaitova V; Motamed D; Schiano T
J Drugs Dermatol; 2014 Feb; 13(2):199-200. PubMed ID: 24509972
[TBL] [Abstract][Full Text] [Related]
3. Drug rash with eosinophilia and systemic symptoms due to telaprevir.
Montaudié H; Passeron T; Cardot-Leccia N; Sebbag N; Lacour JP
Dermatology; 2010; 221(4):303-5. PubMed ID: 20798484
[TBL] [Abstract][Full Text] [Related]
4. [Telaprevir-induced pityriasis rubra pilaris].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 May; 140(5):414-5. PubMed ID: 23663723
[No Abstract] [Full Text] [Related]
5. [Telaprevir in treatment-naïve patients with HCV monoinfection].
Cabezas J; Crespo J; Selmo J; Luis Calleja J
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():7-13. PubMed ID: 24063897
[TBL] [Abstract][Full Text] [Related]
6. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
Macías J; Rivero A
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of hepatitis C infection. A revolution should not hide another].
Sogni P
Presse Med; 2014 Apr; 43(4 Pt 1):339-40. PubMed ID: 24661837
[No Abstract] [Full Text] [Related]
8. [Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].
Tural C; Planas R
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():19-25. PubMed ID: 24063899
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment after short course of telaprevir-based therapy in chronic hepatitis C infected patient.
Dutilh JC; Arends JE
Neth J Med; 2013 Sep; 71(7):391-2. PubMed ID: 24038569
[No Abstract] [Full Text] [Related]
10. [Severe bone marrow aplasia due to triple therapy for hepatitis C virus infection: Apropos of a case].
Bautista Galán C; Serrato AR; Albandea Moreno C; Ruiz Arredondo J
Gastroenterol Hepatol; 2015 Nov; 38(9):542-3. PubMed ID: 25835261
[No Abstract] [Full Text] [Related]
11. Drug induced hypersensitivity syndrome by triple therapy of peginterferon alpha2b, ribavirin and telaprevir in patient with double positive for HBV and HCV.
Takagi H; Hoshino T; Naganuma A; Koitabashi E; Uehara S; Sakamoto N; Kudo T; Ryusaki K; Kakizaki S; Okamoto H
Hepatogastroenterology; 2013 Oct; 60(127):1557-60. PubMed ID: 24627926
[TBL] [Abstract][Full Text] [Related]
12. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Ferenci P; Reddy KR
Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
[TBL] [Abstract][Full Text] [Related]
13. [Possible telaprevir-induced pancreatitis. A case study].
Selvi Sabater P; Espuny Miró A; Muñoz Bertrán ED; Plaza Aniorte J
Farm Hosp; 2013; 37(3):269-70. PubMed ID: 23789806
[No Abstract] [Full Text] [Related]
14. [Conclusions].
Pineda JA
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():49-50. PubMed ID: 24063903
[No Abstract] [Full Text] [Related]
15. [Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
Virolés Torrent S; López Nuñez C; Hombrados Verde M; Figa Francesch M; Ferri Iglesias MJ; Louvriex Freire R; Acero Fernández D
Gastroenterol Hepatol; 2015 Feb; 38(2):78-81. PubMed ID: 24948444
[No Abstract] [Full Text] [Related]
16. Telaprevir for chronic hepatitis C virus infection.
Jesudian AB; Jacobson IM
Clin Liver Dis; 2013 Feb; 17(1):47-62. PubMed ID: 23177282
[TBL] [Abstract][Full Text] [Related]
17. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
Dusheiko G; Wedemeyer H
Gut; 2012 Dec; 61(12):1647-52. PubMed ID: 22936671
[No Abstract] [Full Text] [Related]
18. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
Sitole M; Silva M; Spooner L; Comee MK; Malloy M
Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368
[TBL] [Abstract][Full Text] [Related]
19. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
[TBL] [Abstract][Full Text] [Related]
20. A rare and severe cutaneous adverse effect of telaprevir: drug rash with eosinophilia and systemic symptoms.
Cengiz FP; Su O; Emiroglu N; Biyik Ozkaya D; Bahali AG; Onsun N
G Ital Dermatol Venereol; 2019 Aug; 154(4):488-491. PubMed ID: 31251007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
